Vivideon Therapeutics

Vivideon Therapeutics is a Cambridge-based biotechnology company specializing in the discovery of small molecule drugs that target RNA-modifying enzymes, a field known as epitranscriptomics. Founded by pioneers in the field of epigenetics from the University of Cambridge, the company utilizes a proprietary AI-driven platform to identify and validate novel therapeutic targets within the epitranscriptome. Their primary focus is on developing transformative treatments for various forms of cancer where RNA modification pathways are dysregulated. By integrating deep biological insights with machine learning, Vivideon aims to accelerate the development of precision medicines. The company is currently in the pre-clinical stage, advancing a pipeline of programs focused on high-value oncological targets.